Evidence map›Paper›PMID 37418008›Full record

ArticleCancer immunology, immunotherapy : CII2023

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.

Peiwei Yang, Fan Yu, Zheng Yao, Xu Ding, Hanmei Xu, Juan Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Peiwei Yang *The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, People's Republic of China.
Fan Yu *The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, People's Republic of China.
Zheng YaoThe Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, People's Republic of China.
Xu DingDepartment of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Hanmei XuThe Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, People's Republic of China. xuhanmei6688@126.com.
Juan ZhangAntibody Engineering Laboratory, Department of Molecular Biology, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. zhangjuan@cpu.edu.cn.ORCID http://orcid.org/0000-0003-1067-7878
China Pharmaceutical University · CNNanjing Medical University · CN

Funding

Fundamental Research Funds for the Central Universities 2632023GR08the National Natural Science Foundation NSFC81973223the Project Program of State Key Laboratory of Natural Medicines SKLNMZZ202219
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is a subtype of breast cancer with the highest degree of malignancy and the worst prognosis. The application of immunotherapy for TNBC is limited. This study was to verify the potential application of chimeric antigen receptor-T cells (CAR-T cells) targeting CD24 named as 24BBz in treatment of TNBC. 24BBz was constructed by lentivirus infection and then was co-culture with breast cancer cell lines to evaluate the activation, proliferation and cytotoxicity of engineered T cells. The anti-tumor activity of 24BBz was verified in the subcutaneous xenograft model of nude mice. We found that CD24 gene was significantly up-regulated in breast cancer (BRCA), especially in TNBC. 24BBz showed antigen-specific activation and dose-dependent cytotoxicity against CD24-positive BRCA tumor cells in vitro. Furthermore, 24BBz showed significant anti-tumor effect in CD24-positive TNBC xenografts and T cells infiltration in tumor tissues, while some T cells exhibited exhaustion. No pathological damage of major organs was found during the treatment. This study proved that CD24-specific CAR-T cells have potent anti-tumor activity and potential application value in treatment of TNBC.

Indexed as

Receptors, Chimeric AntigenTriple Negative Breast NeoplasmsAnimalsCD24 AntigenCell Line, TumorHumansImmunotherapyMiceMice, NudeT-LymphocytesCD24 AntigenCD24 protein, humanReceptors, Chimeric AntigenCAR-T cell therapyCD24 antigenSolid tumorTNBC

Identifiers

PMID37418008
PMCPMC10991104
OpenAlexW4383481568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.